Future Oncology

Article	Citations
A Concise Prognostic Score System for Diffuse Large B-Cell Lymphoma: A Retrospective Study with Long-Term Follow-Up	122
Development of a model to predict the prognosis of esophageal carcinoma based on autophagy-related genes	91
The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma	79
Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study	65
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer	55
Crosstalk Between Circrnas and the PI3K/AKT and/or MEK/ERK Signaling Pathways in Digestive Tract Malignancy Progression	52
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis	45
Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe	45
Urothelial Carcinoma in COVID-19: Lessons From a Pandemic and Their Impact on Clinical Practice	45
A Plain Language Summary of the ASCENT Study: Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer	43
Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib	42
Systematic literature review of the epidemiology of neurotrophic tyrosine receptor kinase positive solid tumor sites	41
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)	41
Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma	41
Cost–effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer	40
Diagnosis of chondrosarcoma in a noninvasive way using volatile organic compounds in exhaled breath: a pilot study	40
Should One Use the Combination of Abiraterone and Poly(ADP-ribose) Polymerase Inhibitors as First-Line Therapy for all Patients with Metastatic Castration-Resistant Prostate Cancer?	39
In -Class Transition from Bortezomib-Based Therapy to IRd is an Effective Approach in Newly Diagnosed Multiple Myeloma	38
Sex bias phenomenon in oral cancer: an insight	38
Results of a survey study on health professionals’ perceptions of tumor boards in Brazil	37
Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression	37
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study	36
Brain Injury after Cranial Radiotherapy Combined with Immunotherapy for Brain Metastases in Lung Cancer: A Retrospective Study	35
Targeted Therapy Moves to Earlier Stages of Non-Small-Cell Lung Cancer: Emerging Evidence, Controversies and Future Challenges	34
Can Pretreatment Blood Biomarkers Predict Pathological Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer?	31

Development and Validation of An Immune Gene Set-Based Prognostic Signature in Cutaneous Melanoma	31
Immunotherapy for Liposarcoma: Emerging Opportunities and Challenges	30
A Multicenter, Phase Ib/II, Open-Label Study of Tivozanib with Durvalumab in Advanced Hepatocellular Carcinoma (DEDUCTIVE)	30
The relationship between VDR polymorphisms and keratinocyte carcinomas: a systematic review and meta-analysis	30
Is Obesity a Risk Factor in Cancer Patients with COVID-19?	29
Predicting Amplification of MYCN using CpG Methylation Biomarkers in Neuroblastoma	28
DUART: Durvalumab After Radiotherapy in Patients with Unresectable, Stage III NSCLC who are Ineligible for Chemotherapy	28
A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer	27
Prolonging the lives of African–Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database	26
Combination niraparib and abiraterone for HRR-altered metastatic castration-resistant prostate cancer	26
Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design	26
Sacituzumab Govitecan: Past, Present and Future of a New Antibody–Drug Conjugate and Future Horizon	26
The treatment of advanced pulmonary sarcomatoid carcinoma	25
A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)	25
Overcoming Immunosuppression and Pro-Tumor Inflammation in Lung Cancer with Combined IL-1β and PD-1 Inhibition	25
A plain language summary of the molecular changes in the tumors of people with BRAF V600E–mutant colorectal cancer in the BEACON study	25
Treatment Patterns and Overall Survival in HER2+ Metastatic Breast Cancer at US Community Oncology Practices	24
Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer	24
Association Between Event-Free Survival and Overall Survival in Early-Stage Triple-Negative Breast Cancer	24
Safety and efficacy of anlotinib hydrochloride capsules in advanced non-small-cell lung cancer: a multicenter, real-world study	24
Comparison of tumor-agnostic and tumor-specific clinical oncology trial designs: a systematic review and meta-analysis	24
A Multicenter Randomized, Controlled Clinical Trial of Adjuvant Sintilimab for Esophageal Squamous Cell Carcinoma	24
DOMENICA: dostarlimab versus chemotherapy alone in first-line MMR-deficient advanced endometrial cancer patients	23
Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer	23
Molecular Methods for Increasing the Effectiveness of Ovarian Cancer Treatment: A Systematic Review	23
Real-world results of first-line immunotherapy or targeted therapy for metastatic melanoma in Finland: a cohort study	23
Can we predict the progression of premalignant pancreatic cystic tumors to ductal adenocarcinoma?	22
Real-World Use and Acceptance of Biosimilar Monoclonal Antibodies of Rituximab in Oncology Practice in the USA	22
Serum Exosomal miR-377-3p and miR-381-3p as Diagnostic Biomarkers in Colorectal Cancer	22
Pembrolizumab: First Adjuvant Immunotherapy in Renal Cell Carcinoma?	22
Outcomes of Level of Ligation of Inferior Mesenteric Artery in Colorectal Cancer: a Systematic Review and Meta-Analysis	22
The ‘Hit-and-Run’ Strategy and Viral Carcinogenesis	22
Nivolumab in Metastatic Renal Cell Carcinoma: Results from the Turkish Oncology Group Kidney Cancer Consortium Database	22
Real-World Cost–Effectiveness of Primary Prophylaxis with G-CSF Biosimilars in Patients at Intermediate/High Risk of Febrile Neutropenia	22
Highlights of the San Antonio Breast Cancer Symposium 2020: Part 2	22
Patient preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment	21
Patient Engagement in Cancer Research from the Patient’s Perspective	21
Correction	21
Randomized phase II study comparing neoadjuvant 5-fluorouracil/oxaliplatin/docetaxel versus docetaxel/oxaliplatin/S-1 for patients with type 4 or large type 3 gastric cancer	21
Chemotherapy-free treatment with acalabrutinib can benefit patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were never treated before: a plain language summary of the ELEVATE-	21
Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada	21
ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1 -mutated, metastatic breast cancer	20
REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission	20
Multimodal Analysis of ctDNA Methylation and Fragmentomic Profiles Enhances Detection of Nonmetastatic Colorectal Cancer	20
An MMP-based risk score strongly distinguishes prognosis in hepatocellular carcinoma after resection	20
Real-world adjuvant chemotherapy patterns and outcomes among elderly patients with resected early non-small-cell lung cancer in the USA	20
Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer called MET exon 14 skipping	20
Real-world Evidence of Multiple Myeloma Treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland	20
Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients	19
Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review	19

As a Potential Predictor of Pan-Cancer, UBE2S is Related to Tumor-Associated Macrophage Infiltration	19
Association of human papillomavirus with breast cancer: a new perspective on an old debate	19
Effect of preoperative peripheral blood platelet volume index on prognosis in patients with invasive breast cancer	19
Association of Epstein–Barr virus DNA and SAA with S1 maintenance therapy outcomes in patients with metastatic nasopharyngeal carcinoma	18
Real-world application of next-generation sequencing-based test for surgically resectable colorectal cancer in clinical practice	18
Potential value of tumor stiffness and sE-cadherin in predicting the response to neoadjuvant therapy in HER2-positive breast cancers	17
The Importance of the Glucose-To-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Treated with Sorafenib	17
Next-Generation Sequencing of Cancer Genomes: Lessons Learned	17
Does Failed Mapping Predict Sentinel Lymph Node Metastasis in cN0 Breast Cancer?	17
Small Cell Carcinoma as an Independent Prognostic Factor for Cervical Cancer Patients: A Population-Based Analysis	17
Oncolytic Virotherapy as Promising Immunotherapy Against Cancer: Mechanisms of Resistance to Oncolytic Viruses	17
G-CSF and G-CSF-Related Vasculitis: A Systematic Review of the Literature and Intriguing Future Research Perspectives	17
Upfront Cytoreductive Surgery Versus Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer in Indian Patients	17
Intraperitoneal Infusion of Recombinant Human Endostatin Improves Prognosis in Gastric Cancer Ascites	17
Application and Prospect of Single-Cell Sequencing in Cancer Metastasis	17
LITESPARK-012: Pembrolizumab Plus Lenvatinib With or Without Belzutifan or Quavonlimab for Advanced Renal Cell Carcinoma	16
A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC tri	16
Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study	16
The Benefit of Immunotherapy in Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis	16
Augmented Intelligence to Predict 30-day Mortality in Patients with Cancer	16
Lorlatinib as a treatment for ALK-positive lung cancer	16
Preferences for First-Line Treatment of Advanced Urothelial Carcinoma among US Practicing Oncologists and Patients	16
AMELIORATE: Early Intensification in FLT3 -Mutated Acute Myeloid Leukemia Based on Peripheral Blast Clearance – MYNERVA-GIMEMA AML1919 Trial	15
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer: A Plain Language Summary Of The DESTINY-Gastric01 Study	15
Gastric cancer in pregnancy: a review	15
Potential barriers to implementation of next-generation sequencing in cancer management: a U.S. Physician-based survey	15
Relationship Between Nurses’ Perceptions and Financial Toxicity Management in the Public Health Insurance System	15
Analysis of the Expression Patterns and Clinical Relevance of m 6 A Regulators in 33 Cancer Types	15
Co-expression of CD44v6 and MMP2 predicts lung metastasis and unfavorable prognosis in osteosarcoma	15
Immune Checkpoint Inhibitors Plus Anlotinib Versus Anlotinib Alone as Third-Line Treatment in Advanced Non-Small-Cell Lung Cancer: A Retrospective Study	15
The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer	15
Optimal Examined Lymph Node Count in Node-Negative Colon Cancer Should be Determined	15
Corrigendum	15
Response to letter to editor on the article: Ge W, Chen C, Wu N et al. Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a	15
Plain language summary of a clinical study: anamorelin for treatment of Japanese people with non-small cell lung cancer and cachexia	14
Metabolic syndrome and symptom burden in allogeneic hematopoietic stem cell transplantation survivors	14
Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients	14
A Critical Appraisal on Cancer Prognosis and Artificial Intelligence	13
Clinical Effectiveness of Transcatheter Arterial Chemoembolization Sequential Microwave Ablation For Lack of Blood Supply in Hepatocellular Carcinoma	13
Nomogram to predict overall survival in patients with primary bladder neuroendocrine carcinoma: a population-based study	13
Clinical characteristics of gastrointestinal stromal tumors with lymph node metastasis: a retrospective single-center study	13
Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies	13
Plain language summary and patient perspective of the revised STARS study: long-term results of a study that compared the effectiveness of radiotherapy to surgery in people with non-small-cell lung ca	13
CSF1 Receptor Inhibition of Tenosynovial Giant Cell Tumor Using Novel Disease-Specific MRI Measures of Tumor Burden	13
Cancer staff in an NHS cancer center: infections, vaccination, stress and well-being support during the COVID-19 pandemic	13
Outdoor air pollution and oral cancer: critical viewpoints and future prospects	13
Prognostic Significance of the Systemic Inflammation Response Index in Gastrointestinal Malignancy Patients: A pooled Analysis of 10,091 Participants	13
The prognostic indicator in breast cancer treated with CDK4/6 inhibitors: the prognostic nutritional index	12
An investigator-initiated clinical study in patients with refractory or recurrent solid tumors: ‘R-ISV-FOLactis’ trial	12
Extension of lymph node dissection in the surgical treatment of esophageal and gastroesophageal junction cancer: seven questions and answers	12
Guideline Conformity to the Stupp Regimen in Patients with Newly Diagnosed Glioblastoma Multiforme in China	12
Medicare characteristics, treatment, cost and survival in triple class exposed relapsed or refractory multiple myeloma	12
Deep learning-based multiomics integration model for predicting axillary lymph node metastasis in breast cancer	12
The impact of concomitant therapies on the efficacy and safety of relugolix in advanced prostate cancer	12
Pediatric oncohematological exercise program in hospital: clinical trial study protocol	12
Exploring the Connection Between Microsatellite Instability and Inflammatory Indicators in Cancers	12
A Risk-Group Classification Model in Patients with Bladder Cancer Under Neoadjuvant Cisplatin-Based Combination Chemotherapy	12
Expanded Access to Anticancer Treatments from Conversion to Biosimilar Pegfilgrastim-cbqv in US Breast Cancer Patients	12
Construction of methylation-associated nomogram for predicting the recurrence-free survival risk of stage I–III lung adenocarcinoma	12
Predictors of Poor Precautionary Practices Towards COVID-19 Among Cancer Patients	12
Impact of recurrence on employment, finances, and productivity for early-stage cancer patients and caregivers: US survey	12
Hypersensitivity Reactions to Asparaginase Therapy in Acute Lymphoblastic Leukemia: Immunology and Clinical Consequences	11
Phase II clinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation	11
Long-term outcomes of stage IIB–IV melanoma patients: nationwide data from Norway	11
CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma	11
Interstitial lung disease recurrence on chemotherapy rechallenge in breast cancer: a nationwide Japanese database	11
Systematic Literature Review of Current Treatments for Stage I–III Merkel Cell Carcinoma	11
Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence	11
The Correlation Between Skeletal Muscle Index and Anxiety in Patients with Lung Cancer on the First Day of Chemotherapy	11
Revolutionizing colorectal cancer treatment: unleashing the potential of miRNAs in targeting cancer stem cells	11
Temporal Trends of Adverse Events and Costs of Nivolumab Plus Ipilimumab Versus Sunitinib in Advanced Renal Cell Carcinoma	11
Treatment efficacy score: a better surrogate for arm-level survival differences in neoadjuvant breast cancer trials?	11
Detection and Verification of Coexisting Diagnostic Markers in Plasma and Serum of Patients with Non-Small-Cell Lung Cancer	11
Clinical consensus on treatments for transplant-ineligible newly diagnosed multiple myeloma: double-blinded Delphi panel	11
Association of thyroid function abnormality and prognosis in non-small-cell lung cancer patients treated with PD-1 inhibitors	10
Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studies	10
Tumor mutational burden: why is it still a controversial agnostic immunotherapy biomarker?	10
Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary	10
Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the ‘EVIDENCE’ study	10
KEYNOTE-921: Phase III Study of Pembrolizumab Plus Docetaxel for Metastatic Castration-Resistant Prostate Cancer	10

Perceptions of the COVID-19 vaccine Among Patients With Cancer: A Single-Institution Survey	10
Tebentafusp for the Treatment of Metastatic Uveal Melanoma	10
Palliative and End-Of-Life Symptoms Management for Children with Diffuse Intrinsic Pontine Glioma	10
A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma	10
Pralsetinib in Patients with RET Fusion–Positive Non-Small-Cell Lung Cancer: A Plain Language Summary of the ARROW Study	10
Long-term Results from a Clinical Study of Xevinapant Plus Chemoradiotherapy in People With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: a Plain Language Summary	10
Enzalutamide in biochemically recurrent prostate cancer: key findings from the EMBARK study	10
Evaluation of the prognostic effectiveness of liver metastasis volume by volumetric measurement in colorectal cancer	10
NeoSCORE II: Three Vs Four Cycles of Neoadjuvant Sintilimab + Chemotherapy for Squamous Non-Small-Cell Lung Cancer	10
Methylation site APC 112043544 as a potential biomarker for post-transplant hepatocellular carcinoma recurrence	10
A phase I pharmacokinetic study of lenvatinib in Chinese patients with unresectable hepatocellular carcinoma	10
Research progress on the role of lipoxygenase and its inhibitors in prostate cancer	10
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resist	10
Unsupervised Learning of Cross-Modal Mappings in Multi-Omics data for Survival Stratification of Gastric Cancer	10
Improved Outcomes and Staging in Non-Small-Cell Lung Cancer Guided by A Molecular Assay	10
Engineered exoASO-STAT6: a potent monotherapy for oral squamous cell carcinoma	10
Reliability, Validity and Important Difference Estimates for the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18)	9
Real-World Outcomes of Pomalidomide Therapy after Lenalidomide Induction in Relapsed/Refractory Multiple Myeloma	9
Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis	9
Benefit-Risk Trade-Offs in Treatment Choice in Advanced HER2 Negative Breast Cancer: Patient and Oncologist Perspectives	9
Treatment patterns in advanced/metastatic non-small-cell lung cancer in China: results from the CancerMPact ® survey 2021	9
Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis	9
Treatment of advanced urothelial cancer with nivolumab plus chemotherapy versus chemotherapy alone (CheckMate 901 study): a plain language summary	9
Methylated ZNF582 as a triage marker for occult cervical cancer and advanced cervical intraepithelial neoplasia	9
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer	9
Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma	9
Retrospective study of total neoadjuvant therapy for locally advanced rectal cancer	9
Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion	9
Perspective on the Risk of Suicide Associated with Oral Cancer Diagnosis	9
Impact of comorbidity on immune-related adverse events and survival in older cancer patients treated with immunotherapy	9
The JAVELIN Bladder Medley Trial: Avelumab-Based Combinations as First-Line Maintenance in Advanced Urothelial Carcinoma	9
Efficacy of Trastuzumab and Potential Risk Factors on Survival in Patients with HER2-Positive Metastatic Gastric Cancer	9
Keeping the Balance, the True Major Goal in Advanced Sarcoma	9
Safety and efficacy of left colic artery preservation in laparoscopic anterior resection for lower rectal cancer	9
Real-World Ibrutinib dose Reductions, Holds and Discontinuations in Chronic Lymphocytic Leukemia	9
Disease landscape of advanced HER2-breast cancer patients by treatment line in three EU countries and USA	9
E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors—design and rationale	9
Desmoid Fibromatosis: is the Current Picture Changing?	9
DRP1: shedding light on the complex nexus of mitochondrial fission and breast cancer	9
Prognostic role of prognostic nutritional index in patients with lymphoma-associated hemophagocytic lymphohistiocytosis	8
Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy	8
Extended distal pancreatectomy in pancreatic cancer: is it justified? A systematic review of literature	8
Association of Polymorphisms in PIN1 with Progression And Susceptibility in Gastric Cancer	8
PALVEN: Phase Ib Trial of Palbociclib, Letrozole and Venetoclax in Estrogen Receptor- and BCL2-Positive Advanced Breast Cancer	8
Alpha radioligand therapy in neuroendocrine neoplasms: current landscape and spotlight on RYZ101	8
The Role of Surgery in Metastatic Cancer: The Case For a Pragmatic Tumor-Agnostic Randomized Trial	8
Treatment patterns and outcomes in advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in China	8
Development and validation of a Cancer Patient Suicidal Ideation Scale	8
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data	8
Real-world outcomes of patients with metastatic endocrine-responsive breast cancer receiving palbociclib-based combinations	8
Downregulation of ACE2 is associated with advanced pathological features and poor prognosis in clear cell renal cell carcinoma	8
Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma	8
Assessing the quality of patient-reported outcome measurements for gynecological cancers: a systematic review	8
Current practices for the management of advanced high-grade epithelial ovarian cancer in the UK: OC-NOW survey (2023)	8
Correction	8
Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis	8
Real-world Management Patterns in EGFR -mutant Advanced Non-Small-Cell Lung Cancer before First-Line Adoption of Osimertinib: The REFLECT Study in Greece	8
Prognostic Value of GPC5 Polymorphism rs2352028 and Clinical Characteristics in Chinese Lung Cancer Patients	8
Nivolumab in unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma	8
NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned?	8
Cetuximab Every 2 Weeks Versus Standard Weekly Dosing Administration Schedule	8
The Management of a Breast Unit During the COVID-19 Emergency: A Local Experience	8
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for hepatocellular carcinoma: a meta-analysis	8
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial	8
TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases	8
Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma	8
Value of Biomarkers in Epithelial–Mesenchymal Transition Models Of Liver Cancer Under Different Interventions: A Meta-Analysis	8
Clinical Application of Serum Tumor Abnormal Protein Combined with Tumor Markers in Lung Cancer Patients	8
A randomized phase II study comparing preoperative mFOLFOX6 versus FOLFOXIRI for locally advanced colon cancer: JCOG2006	8
Optimizing total neoadjuvant therapy in locally advanced rectal cancer: risk stratification should not be overlooked	8
Characterization of the immune environment in pregnancy-associated breast cancer	8
Prognostic Factors Affecting Infantile Medulloblastoma Outcomes in the Molecular Era: A 12-year Single-Center Experience from Egypt	7
The Implications from the Interplay of Neoadjuvant Chemoradiotherapy and the Immune Microenvironment in Rectal Cancer	7
First Advanced Course on Biomarkers in Molecular and Immuno-Oncology in the Middle East	7
The impact of myelosuppression on quality of life of patients treated with chemotherapy	7
Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma	7
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer	7
Financial Toxicity and its Impact on Health Outcomes and Caregiver Burden Among Adult Cancer Survivors in the USA	7
The first Middle East and North Africa expert consensus recommendations for management of advanced gastric cancer	7
Highlights of the San Antonio Breast Cancer Symposium 2020: Part 1	7
Margetuximab in HER2-positive metastatic breast cancer	7
A genome-wide association study using HapMap cell lines reveals modulators of cellular response to cyclophosphamide	7
Plain language summary and patient perspective of the 2020 lung cancer screening recommendations by the US Preventive Services Task Force	7
Exploring Exosome Data to Identify Prognostic Gene Signatures for Lung Adenocarcinoma	7
Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China	7
Post-marketing surveillance of tirabrutinib in 189 patients with r/r primary central nervous system lymphoma	7
Prognostication for Surgically Treated Papillary Renal Cell Carcinoma: Which Model is the Optimal Choice?	7
Real-world treatment of large B-cell lymphoma with chimeric antigen receptor T-cell therapy after loncastuximab tesirine: a plain language summary	7
The Effects of Managing Cancer and Living Meaningfully (CALM) on Psychological Distress in Esophageal Cancer Patients	7
Cancer cytogenetics in the era of artificial intelligence: shaping the future of chromosome analysis	7
Matching-Adjusted Indirect Comparison of Amivantamab vs Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer	7
Corrigendum	7
Effect of Lateral Lymph Nodes Without Malignant Characteristics on the Prognosis of Patients with Rectal Cancer	7
Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary	7
KRAS mutational analysis: a new supplementary diagnostic tool for extrahepatic biliary stenosis	7